Ranbaxy Laboratories on Wednesday said it has received USFDA tentative approval for Sumatriptan Succinate tablets.
The company has got the tentative approval from USFDA to manufacture and market Sumatriptan Succinate tablets in 25 mg (base), 50 mg (base) and 100 mg (base), a Ranbaxy release said.
Sumatriptan Succinate tablets are used for the acute treatment of migraine attacks with or without aura in adults, it said.
"We are pleased to receive this tentative approval for Sumatriptan Succinate Tablets. This product represents a future opportunity for Ranbaxy and will be launched following final approval from the FDA that will further expand our growing portfolio of affordable generic product formulations," said Jim Meehan, vice president of sales and marketing for Ranbaxy Pharmaceuticals Inc, USA.